Phase I dose-escalation study of CYT997 given as a 24-hour intravenous infusion every three weeks in patients with advanced solid tumours
Phase of Trial: Phase I
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Lexibulin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors YM BioSciences Australia
- 08 Sep 2010 Results from this trial have been published in the British Journal of Cancer according to a YM Biosciences media release. The results are discussed further within the media release.
- 24 Aug 2010 Results from this trial were published in the British Journal of Cancer.
- 26 May 2008 New trial record.